Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

EBS stock hub

Emergent BioSolutions Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

EBSis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

490.2M

NYSE

Market data

Live price

Current market quote for this ticker.

Current price

EBS

In the news

Latest news · EBS

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.6P50 18.3P75 33.7

Trailing P/En/a

P25 15P50 23.3P75 38.5

ROE-1.6

P25 -106.6P50 -46.9P75 -3.1

ROIC-20

P25 -63.1P50 -27.5P75 -0

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All EBS market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

238

Groups with data

Currency

USD

Showing 238 of 238 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001367644
Company name	Emergent BioSolutions Inc.
Country	United States
Country code	US
Cusip	29089Q105
Employees	900
Employees Change	-700%
Employees Change Percent	-43.75
Enterprise value	$914.5M
Exchange	NYSE
Financial currency	USD
First seen	2026-05-09
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2006-11-15
Isin	US29089Q1058
Last refreshed	2026-05-10
Market cap	$490.2M
Market cap category	Small-Cap
Price	$9.5
Price currency	USD
Rev Per Employee	752,000x
Sector	Healthcare
Sic	2834
Symbol	EBS
Website	https://www.emergentbiosolutions.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-1.75%
EV Sales Forward	1.53x
EV/EBIT	12.14x
EV/EBITDA	5.49x
EV/FCF	6.75x
EV/Sales	1.35x
FCF yield	27.62%
P/B ratio	0.94x
P/S ratio	0.72x
PE Ratio10 Y	46.87x
PS Forward	0.82x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	11.13%
EBITDA Margin	24.63%
FCF margin	20.01%
Gross margin	47.49%
Gross Profit	$321.4M
Gross Profit Growth	10.67%
Gross Profit Growth Q	-38.38%
Gross Profit Growth3 Y	26.15%
Gross Profit Growth5 Y	-19.93%
Net Income	$-8.6M
Net Income Growth Q	-90%
Net Income Growth Years	2%
Pretax Margin	0.52%
Profit Margin	-1.27%
Profit Per Employee	$-9,556
Profitable Years	1
ROA	3.43
Roa5y	1.02
ROCE	6.43
ROE	-1.6
Roe5y	-19.53
ROIC	-20.02
Roic5y	0.76

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-12.44%
Cagr15y	-5.31%
Cagr1y	100.52%
Cagr3y	1.97%
Cagr5y	-31.2%
EPS Growth Q	-93.75
EPS Growth Years	2
FCF Growth	43.43%
FCF Growth5 Y	-15.29%
OCF Growth	34.42%
OCF Growth10 Y	-0.3%
OCF Growth5 Y	-21.08%
Revenue Growth	-29.89x
Revenue Growth Q	-29.75x
Revenue Growth Years	0x
Revenue Growth3 Y	-11.44x
Revenue Growth5 Y	-16.88x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.49
Assets	$1.3B
Cash	$160.3M
Current Assets	$637.6M
Current Liabilities	$148.7M
Debt	$584.6M
Debt EBITDA	$3.51
Debt Equity	$1.12
Debt FCF	$4.32
Equity	$523.1M
Interest Coverage	1.35
Liabilities	$797.3M
Long Term Assets	$682.8M
Long Term Liabilities	$648.6M
Net Cash	$-424.3M
Net Cash By Market Cap	$-86.56
Net Debt EBITDA	$2.55
Net Debt Equity	$0.81
Net Debt FCF	$3.13
Tangible Book Value	$52.7M
Tangible Book Value Per Share	$1.02
WACC	-4.93

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	4.29
Inventory Turnover	1.11
Net Working Capital	$331M
Quick ratio	1.9
Working Capital	$488.9M
Working Capital Turnover	$1.25

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	1.26%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-73.49%
1Y total return	100.42%
200-day SMA	9.65
3Y total return	6.03%
50-day SMA	8.35
50-day SMA vs 200-day SMA	50under200
5Y total return	-84.58%
All Time High	137.6
All Time High Change	-93.1%
All Time High Date	2020-08-06
All Time Low	1.42
All Time Low Change	569.01%
All Time Low Date	2024-02-06
ATR	0.48
Beta	2.33
Beta1y	2.82
Beta2y	2.83
Ch YTD	-23.14
High	9.64
High52	14.06
High52 Date	2026-01-07
High52ch	-32.43%
Low	9.1
Low52	5.31
Low52 Date	2025-05-15
Low52ch	79.08%
Ma50ch	13.81%
Premarket Change Percent	-0.2
Premarket Price	$9.11
Premarket Volume	9,592
Price vs 200-day SMA	-1.52%
RSI	66.61
RSI Monthly	48.62
RSI Weekly	50.69
Sharpe ratio	1.14x
Sortino ratio	2.23
Total Return	1.26%
Tr YTD	-23.14
Tr15y	-55.86%
Tr1m	21.02%
Tr1w	12.16%
Tr3m	-13%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	1
Analyst Ratings	Strong Buy
Earnings EPS Estimate	$-0.25
Earnings Revenue Estimate	157,400,000x
Earnings Revenue Estimate Growth	-29.16x
Operating Income	$75.3M
Operating Income Growth Q	-79.17
Operating Income Growth5 Y	-34.02
Operating margin	11.13
Price target	$12
Price Target Change	$26.32

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	46,949,865%
Float Percent	90.99%
Net Borrowing	-112,500,000
Shares Insiders	2%
Shares Institutions	79.55%
Shares Out	51,596,296
Shares Qo Q	7.82%
Shares Yo Y	-1.26%
Short Float	20.54%
Short Ratio	12.21
Short Shares	18.69

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$118.8M
Average Volume	667,076.25x
Bv Per Share	10.1
CAPEX	$-12.6M
Ch10y	-75.2
Ch15y	-58.7
Ch1m	21.02
Ch1w	12.16
Ch1y	100.4
Ch3m	-13
Ch3y	6.03
Ch5y	-84.58
Ch6m	-6.5
Change	4.05%
Change From Open	4.05
Close	9.13
Days Gap	0
Depreciation Amortization	91,400,000
Dollar Volume	9,333,503
Earnings Date	2026-04-30
Earnings Time	amc
EBIT	$75.3M
EBITDA	$166.7M
EPS	$-0.21
F Score	5
FCF	$135.4M
FCF EV Yield	14.81x
FCF Per Share	$2.62
Financing CF	-147,600,000
Fiscal Year End	December
Founded	1,998
Income Tax	$12.1M
Investing CF	7,500,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-04-30
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-27
Ma150	10.18
Ma150ch	-6.65%
Ma20	8.5
Ma20ch	11.75%
Net CF	8,700,000
Next Earnings Date	2026-08-05
Open	9.13
Optionable	Yes
P FCF Ratio	3.62
P OCF Ratio	3.31
Position In Range	74.07
Post Close	9.5
Postmarket Change Percent	0.95
Postmarket Price	$9.59
Ppne	209,300,000
Pre Close	9.13
Price Date	2026-05-08
Price EBITDA	$2.94
Ptbv Ratio	9.3
Relative Volume	1.47x
Revenue	676,800,000x
SBC By Revenue	2.45x
Share Based Comp	16,600,000
Tax By Revenue	1.79x
Tax Rate	345.71%
Tr6m	-6.5%
Us State	Maryland
Volume	982,474
Z Score	1.33

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does EBS pay a dividend?

Capital-return profile for this ticker.

Performance

EBS stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns EBS?

Insider, institutional, and short-interest positioning.

Institutional ownership

+79.6%

Float: +91.0% of shares outstanding

Insider ownership

+2.0%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

EBS momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

66.6

Neutral momentum band

Price vs 200-day MA

-1.5%

50/200-day relationship not available

Beta (5Y)

2.33

More volatile than the market

Sharpe ratio

1.14

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About EBS

Hub-level FAQ points readers to the deeper analysis pages.

What is the current EBS stock rating?

Emergent BioSolutions Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full EBS analysis?

The full report lives at /stocks/EBS/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for EBS?

The latest report frames EBS around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the EBS page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.